Epigenetics
How does lactylation-driven ALKBH3 weaken tumor suppressors?
Open access · cc by · source: Europe PMC
Histone lactylation boosts ALKBH3, which removes m1A from SP100A and diminishes PML nuclear condensates, accelerating ocular melanoma progression.
How this study connects
Role on claims
Each row is a claim on a concept or method page where this paper supports, challenges, or qualifies the statement. Roles are hand-checked — not a model guess.
The rescue experiment places SP100A on the path rather than beside it.
Lactylation acts through downstream enzymes, not only through general chromatin state. In high-risk ocular melanoma, lactylation-linked upregulation of ALKBH3 accompanied m1A hypomethylation; demethylating SP100A impaired PML body formation, and silencing ALKBH3 had therapeutic efficacy that SP100A depletion reversed.
Evidence for the claim as stated.
Inspect source passages
How does lactylation-driven ALKBH3 weaken tumor suppressors?
These passages occur verbatim in the stored paper text. They support the points listed below; they do not verify every statement in the explanation.
Authors report ALKBH3 silencing shows efficient therapeutic efficacy in melanoma in vitro and in vivo.
Therapeutically, the silencing of ALKBH3 exhibits efficient therapeutic efficacy in melanoma both in vitro and in vivo , which could be reversed by the depletion of SP100A.
Abstract frames lactylation-enhanced ALKBH3 as attenuating PML condensates via SP100A m1A removal.
Herein, we found that histone lactylation enhances ALKBH3 expression and simultaneously attenuates the formation of tumor-suppressive promyelocytic leukemia protein (PML) condensates by removing the m 1 A methylation of SP100A, promoting the malignant transformation of cancers.
Key findings
ALKBH3 is upregulated in high-risk ocular melanoma with lactylation-linked m1A hypomethylation. Demethylating SP100A impairs PML body formation; ALKBH3 silencing has therapeutic efficacy that SP100A depletion can reverse. YTHDF1 recognizes methylated SP100A transcript.
Methodology
Mapped ALKBH3 upregulation under high histone lactylation, identified SP100A as an ALKBH3 m1A target via multiomics, and tested silencing plus YTHDF1 recognition mechanisms in melanoma models.
Limitations
Does not establish a ready-to-use clinical ALKBH3 inhibitor regimen; ocular melanoma findings may not transfer unchanged to all cancers.
Related papers in this topic
Same topic cluster — not a recommendation engine.